Ann: Appendix 4C - quarterly, page-2

Yesterday's Quarterly Investor Call provided some light at the end of the tunnel imho.
Barnes often wanders off-script, and he expanded on two important points:

At 11:12 minutes into the recording he states "In the US, I can report that discussions with a number of quality distribution partners have progressed during the recent holiday break. We have previously given guidance that distributor appointments will occur this year. We are now signalling this will occur during the 1st half of this year"

Separate report in the Quarterly pointed out the FDA extending its deadline to 31 May 2021 would not impact distributor appointments. So Distribution Partner/s could be appointed in the US anytime between today and 30 June?

At 21:15 minutes (into the Q & A section now), Barnes answers a question from Liam regarding size of Labs being targeted. Barnes provides some insight into the French market; a new territory for CCS/LBT. "France has many more segregated labs, less mega labs. France has a restriction on the Km range that a specimen can travel. This results in more, smaller labs than say a market like Germany. France is a federated environment.
France is very tech/AI oriented. This will make it easier to engage lab staff on the AI front."

GLTAH